The AI for pharma generics sourcing. Ask any sourcing question and get a cited answer from the PharmaGraph in minutes, saved as a shareable brief.
export_country, import_country, molecule_id, n_shipments, median_usd_per_kg.canonical_name, hq_country, ownership_type, ticker, industry.product_id, entity_id, manufacturer_entity_id, approval_status.name, country, entity_id, fda_fei, business_type.event_type, regulator, severity, plant_id, entity_id.person_uid, company_id, job_title, is_current, start_year.Open a chat in PharmaDB. Type the sourcing question your team is currently building from Excel.
pharmagraph_schema SELECT holder, plant, capacity_kg … The AI picks the right tables, runs the SQL, joins regulatory and inspection data, applies counterparty anonymisation, and writes back in the chat.
Ask the AI to write it up. You get a citation-anchored note or an interactive page you can share with your team via a link.
One product, one login, one bill. The dataset reads in either direction. Buyers bring a molecule, a dosage form, and a destination market. Suppliers bring a portfolio and a manufacturing or service footprint (API plants, FDF lines, CDMO capacity). The dataset is the same. The question is what differs.
Filter active suppliers by regulatory status (DMF, CEP, ANDA holder, contract manufacturer), plant inspection history, recent shipment volume, product form, and exclusivity. Ranked against your destination market, anchored to clearance records.
Herfindahl-Hirschman Index, top-3 exporter share, and active-exporter count per molecule-lane. Surface registered second-source candidates with capacity headroom and clean inspection records.
p25, median, and p75 unit-price benchmarks by molecule and country-pair (the lane). Aggregated to protect counterparty identity. Sourced from customs clearance records, never from vendor brochures or syndicated panels.
For each molecule you manufacture, see destination countries growing in import volume where your supplier share sits below the median for that lane. Aggregate trade data only. No named buyers.
HHI above 0.40 indicates single-source structural exposure on a buyer-side lane. Importers in those lanes are actively qualifying second sources. Approach with a registered supply story, not a cold pitch.
p25, median, and p75 unit-price benchmarks for the lane you're bidding into, anchored to the last 24 months of clearance records. Walk into the tender with the actual clearing range.
The first time pharma sourcing felt like a working dataset, not a quarterly bespoke project.VP, BD · Indian pharma manufacturer · 2026
We run them on PharmaDB, on screen, in a 30-minute working session. You keep the answers. No deck, no pitch.